Wire · operational-macro
Teva Completes Denosumab Biosimilar Pair With FDA Nod for Degevma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
The FDA approved Teva's Degevma, a denosumab biosimilar to Xgeva, completing its oncology-related bone disease biosimilar portfolio alongside Ponlimsi, approved earlier in 2026. This approval expands patient access options for cancer-related bone complications and comes amid an increasingly competitive market where pricing and payer decisions will drive adoption.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 28 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You face a growing biosimilar market where winning depends on pricing and payer deals, not just approvals. Getting ahead means targeting payers and providers who control access as more denosumab options emerge.
◆ Coverage
3 sources · first reported 28 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics